Core Insights - Serina Therapeutics' CEO, Steven Ledger, will present at a webinar discussing the impact of new FDA initiatives on drug development and investor expectations in the life sciences sector [1][2] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications using its proprietary POZ Platform™ [5] - The POZ Platform™ aims to enhance the efficacy and safety profiles of various drug modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs) [5] Event Details - The webinar titled "Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences" is scheduled for February 4, 2026, at 8:30 AM Pacific / 11:30 AM Eastern [1] - Participants can submit questions for the CEO before and during the event, which will be hosted by Tribe Public's Managing Member, John F. Heerdink, Jr. [4]

Company Overview - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications using its proprietary POZ Platform™ technology [7] - The company is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [7] Industry Context - The biotechnology sector is currently experiencing a bear market, with approximately 25% of the 700 to 800 publicly traded US biotech companies having negative enterprise values [3] - The upcoming webinar event titled "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?" aims to discuss investment opportunities in this challenging environment [2][3] Event Details - Serina's CEO, Steven A. Ledger, will present at the Tribe Public's Webinar on June 11, 2025, at 8:30 am Pacific / 11:30 am Eastern [2] - Participants can submit questions for the CEO before and during the event, which will be hosted by Tribe Public's Managing Member, John F. Heerdink, Jr. [6]